SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gains as its arm launches first Reference Laboratory in Kolkata

11 Mar 2022 Evaluate

Lupin is currently trading at Rs. 743.55, up by 4.15 points or 0.56% from its previous closing of Rs. 739.40 on the BSE.

The scrip opened at Rs. 739.50 and has touched a high and low of Rs. 746.75 and Rs. 739.35 respectively. So far 5936 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 678.65 on 07-Mar-2022.

Last one week high and low of the scrip stood at Rs. 752.15 and Rs. 678.65 respectively. The current market cap of the company is Rs. 33602.09 crore.

The promoters holding in the company stood at 46.81%, while Institutions and Non-Institutions held 40.39% and 12.79% respectively.

Lupin’s 100% subsidiary -- Lupin Diagnostics has launched its first Reference Laboratory in East India in Kolkata. The new Reference Laboratory at Kolkata has capabilities to conduct a broad spectrum of routine and specialized tests in the fields of molecular diagnostics, cytogenetics, flow cytometry, histopathology, cytology, microbiology, serology, haematology, immunology and routine biochemistry. 

The company is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region. These processing labs will be located in the cities of Siliguri, Berhampore, Asansol, Burdwan and Bankura in West Bengal, along with Guwahati (Assam), Patna (Bihar), Ranchi and Dhanbad (Jharkhand) and Bhubaneshwar (Orissa). These labs will be connected to Lupin’s franchise collection centers, LupiMitra. Lupin Diagnostics has more than 100 LupiMitra already enrolled for its East India operations. 

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×